Citations 1
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
Chen, Alice P. , Rosenberger, Christina L. , Moore, Nancy, Foster, Jared C. , Naqash, Abdul Rafeh , Sharon, Elad , Coyne, Geraldine O’Sullivan , Schwartz, Gary K. , Riedel, Richard F. , Glod, John, Hu, James , Read, William L., Merriam, Priscilla , Deshpande, Hari A., Ladle, Brian H. , Okuno, Scott H. , Beck, Jill C., Chen, J Y, Ferry‐Galow, Katherine V., Fino, Kristin, Wilsker, Deborah, Begum, Asma , Parchment, Ralph E. , Doroshow, James H. , O'Sullivan Coyne, Geraldine , Conley, Anthony P , Burgess, Melissa A , Davis, Elizabeth J , Merriam, Priscilla , Ladle, Brian H , Okuno, Scott , Chen, James L , Ferry-Galow, Katherine V , Miller, Brandon L , Wilsker, Deborah F , Doroshow, James H , Riedel, Richard F , Sharon, Elad , Naqash, Abdul Rafeh , Schwartz, Gary K , Moore, Nancy, Glod, John , Conley, Anthony P. , Read, William, Burgess, Melissa , Davis, Elizabeth J. , Deshpande, Hari A.
Journal of Clinical Oncology | April 18, 2026 | Volume: 44 | Issue: 16 | Pages: 1490-1497
We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.